Stanley-Laman Group’s Meridian Bioscience Inc VIVO Stock Holding History

Stanley-Laman Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-47,942	Closed	-$988K	–	352
2016 Q1	$988K	Sell	47,942 -100,291	-68%	-$1.98M	0.19%	115
2015 Q4	$3.04M	Buy	148,233 +76,042	+105%	+$1.46M	0.52%	59
2015 Q3	$1.23M	Sell	72,191 -5,363	-7%	-$98K	0.25%	100
2015 Q2	$1.45M	Sell	77,554 -2,386	-3%	-$44.2K	0.27%	102
2015 Q1	$1.52M	Buy	79,940 +17,289	+28%	+$320K	0.28%	97
2014 Q4	$1.03M	Sell	62,651 -23,771	-28%	-$408K	0.2%	123
2014 Q3	$1.53M	Sell	86,422 -1,702	-2%	-$33.4K	0.3%	102
2014 Q2	$1.82M	Sell	88,124 -10,239	-10%	-$210K	0.33%	94
2014 Q1	$2.14M	Buy	+98,363	New	+$2.25M	0.37%	84

Other funds holding VIVO

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stanley-Laman Group's VIVO Position: Q2 2016 in Review

Stanley-Laman Group sold out of Meridian Bioscience Inc (VIVO) in Q2 2016, closing a stake of 47,942 shares — an estimated $988K sold.

Stanley-Laman Group first reported a position in VIVO in Q1 2014 and held it in 9 quarters. The position peaked at $3.04M in Q4 2015. 180 funds tracked by Wall St. Rank hold VIVO as of Q2 2016.

Stanley-Laman Group reported no remaining Meridian Bioscience Inc position as of Q2 2016 after selling out during the quarter.
Stanley-Laman Group sold 47,942 Meridian Bioscience Inc shares in Q2 2016, an estimated $988K.
Stanley-Laman Group first reported a position in Meridian Bioscience Inc in Q1 2014 and held it in 9 quarters.
Stanley-Laman Group's Meridian Bioscience Inc position peaked at $3.04M in Q4 2015.
180 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2016.

Based on Stanley-Laman Group's 13F filing for Q2 2016, filed 4 Aug 2016.